Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T1KL
|
|||
| Former ID |
DIB012594
|
|||
| Drug Name |
Pankomab-GEX
|
|||
| Synonyms |
GT-MAB 2.5 GEX; PankoMab (GlycoExpress, cancer), Glycotope
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Glycotope GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01899599) PankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.